{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pregnant+Woman+With+Single+Pregnancy", "query": { "condition": "Pregnant Woman With Single Pregnancy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 669, "total_pages": 67, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pregnant+Woman+With+Single+Pregnancy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T02:06:14.336Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02502266", "title": "Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pegylated Liposomal Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 582, "start_date": "2016-05-03", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 370, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02502266" }, { "nct_id": "NCT00526656", "title": "Sunitinib in Treating Patients With Locally Advanced Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2007-09", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00526656" }, { "nct_id": "NCT03978624", "title": "Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Procedure/Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 20, "start_date": "2020-09-23", "completion_date": "2026-11-22", "has_results": true, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03978624" }, { "nct_id": "NCT03612856", "title": "Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End Stage Renal Disease", "Thrombosis" ], "interventions": [ { "name": "AB023- Dose 1", "type": "DRUG" }, { "name": "AB023-Dose 2", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aronora, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 27, "start_date": "2018-10-29", "completion_date": "2019-07-06", "has_results": true, "last_update_posted_date": "2024-03-07", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03612856" }, { "nct_id": "NCT00698451", "title": "A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms" ], "interventions": [ { "name": "doxorubicin HCL liposome; bevacizumab; carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 54, "start_date": "2008-08", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2013-09-06", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 1, "location_summary": "Horsham, Pennsylvania", "locations": [ { "city": "Horsham", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00698451" }, { "nct_id": "NCT05457283", "title": "A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease", "Proteinuria", "Children" ], "interventions": [ { "name": "Finerenone (Kerendia, BAY94-8862)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 100, "start_date": "2022-11-08", "completion_date": "2028-12-28", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05457283" }, { "nct_id": "NCT04871529", "title": "Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall", "Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma", "Stage II Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-08-10", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2024-12-30", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 92, "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Highlands Ranch", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT04871529" }, { "nct_id": "NCT07676474", "title": "Continuous Wireless Ultrasound to Monitor Fetal Health", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pregnant Woman With Single Pregnancy", "Ultrasound Fetal Medicine" ], "interventions": [ { "name": "Wireless Ultrasound Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2026-06-30", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07676474" }, { "nct_id": "NCT03087942", "title": "Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Insufficiency" ], "interventions": [ { "name": "QAW039", "type": "DRUG" }, { "name": "QAW39A", "type": "DRUG" }, { "name": "QAW39A2107", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 45, "start_date": "2017-07-05", "completion_date": "2018-08-07", "has_results": false, "last_update_posted_date": "2020-12-11", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03087942" }, { "nct_id": "NCT03678883", "title": "9-ING-41 in Patients With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer", "Pancreatic Cancer", "Sarcoma", "Renal Cancer", "Refractory Cancer", "Refractory Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Pancreatic Adenocarcinoma", "Resistant Cancer", "Neoplasm Metastasis", "Neoplasm of Bone", "Neoplasm, Breast", "Neoplasm of Lung", "Neoplasms,Colorectal", "Neoplasms Pancreatic", "Malignant Glioma", "Malignancies", "Malignancies Multiple", "Bone Metastases", "Bone Neoplasm", "Bone Cancer", "Pancreas Cancer", "Pancreatic Neoplasms", "Breast Neoplasms", "Acute T Cell Leukemia Lymphoma" ], "interventions": [ { "name": "9-ING-41", "type": "DRUG" }, { "name": "Gemcitabine - 21 day cycle", "type": "DRUG" }, { "name": "Doxorubicin.", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" }, { "name": "Carboplatin.", "type": "DRUG" }, { "name": "Nab paclitaxel.", "type": "DRUG" }, { "name": "Paclitaxel.", "type": "DRUG" }, { "name": "Gemcitabine - 28 day cycle", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actuate Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2019-01-04", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-07-23T02:06:14.336Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03678883" } ] }